Pipeline
Our platform and pipeline based on core patented assets
Core Assets
Our platform and pipeline is based on core patented assets licensed from leading pharmaceutical companies, device companies and academic medical institutions.
These assets include exclusive, worldwide licenses to two Phase 2 drugs with clinical POC, a breakthrough ultrasound device + drug platform for cancer vaccination, and proprietary approaches for integrating drugs, energy devices, and cell therapy to achieve patient outcomes that cannot be achieved with each standalone therapy.
Pipeline Timelines
Our pipeline starts with strong, patented assets with near-term indications.
Oncology
Lead Indication:
Non-small Cell Lung Cancer (NSCLC)
Product
Drug X + Radiation
Next Key Milestone
A comprehensive pipeline is available via a NDA. For more information, please contact us.
Oncology
Other Cancer
Product
Drug X +/- Drug Y + Radiation
Next Key Milestone
A comprehensive pipeline is available via a NDA. For more information, please contact us.
Hematologic Disorders
Lead Indication:
Thrombocytopenia in Low-risk Myelodysplastic Syndrome
Product
Drug Y
Next Key Milestone
A comprehensive pipeline is available via a NDA. For more information, please contact us.
